Username:

Password:
GO
Forgotten your login details? Click here

EXPERIMENTAL AND IN SILICO APPROACHES TO TARGET SELECTION AND TRACTABILITY FOR DRUG DISCOVERY

Joint meeting with the SCI

Monday 21st March 2022
The Francis Crick Institute, 1 Midland Road, London NW1 1AT
REGISTRATION NOW CLOSED


This meeting is sponsored by:

           

PROGRAMME - all times are UK time (GMT)

09.00 - 10.00 Arrival, registration and coffee
10.00 - 10.30 Welcome and introduction -
Mike Hann, GSK, UK
Targeted covalent inhibitors and molecular superglues
Lyn Jones, Dana-Farber Cancer Institute, Boston, USA
 
Session 1 - Part 1: Sources of target hypotheses for drug discovery
10.30 - 11.00 The utility of human genetics, clinical samples and collaboration in drug discovery for IPF
Jessica Eley, GSK, Stevenage, UK
11.00 - 11.30 Using Systems Biology to Discover Novel Targets for Neurological Diseases
Victor Neduva, MSD, London, UK
 
11.30 - 12.00 Coffee break
 
Session 1 - Part 2: Sources of target hypotheses for drug discovery
12.00 - 12.30 Chemogenomic screening to identify novel mechanisms which selectively kill HIV infected cells
Deb Rothman, Merck, USA
12.30 - 13.00 Single cell atlases of the gut to discover and prioritise druggable targets
Rasa Elmentaite, Teichmann Group, University of Cambridge, UK
 
13.00 - 14.00 Lunch break
 
Session 2: Practicalities of assessing target intervention opportunities
14.00 - 14.30 In silico target identification and prioritisation in the era of new drug modalities
Andrew Leach, EBI, Cambridge, UK
14.30 - 15.00 Adapting to a changing portfolio landscape: an industry perspective of experimental approaches to assess target tractability and hit finding
Ian Storer, AZ, Cambridge, UK
15.00 - 15.30 Affinity Selection Mass Spectrometry for Experimental Tractability Assessment
Joe Kozole, GSK, Philadelphia, USA
15.30 - 16.00 Novel Therapeutic Targets for Treatment of Neurodegeneration
Paul Brennan, University of Oxford, UK 
 
16.00 Closing comments and meeting close
OVERVIEW
PROGRAMME